A Feasibility Study to Undertake a Definitive Randomised Multi-centre, Double-blind, Double-dummy Controlled Study of a Novel Agent Anakinra vs. Depo-Medrone for Acute Gout Attacks in Patients With Moderate Chronic Kidney Disease

Trial Profile

A Feasibility Study to Undertake a Definitive Randomised Multi-centre, Double-blind, Double-dummy Controlled Study of a Novel Agent Anakinra vs. Depo-Medrone for Acute Gout Attacks in Patients With Moderate Chronic Kidney Disease

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 19 Jul 2016

At a glance

  • Drugs Anakinra (Primary) ; Methylprednisolone
  • Indications Cryopyrin-associated periodic syndromes; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms ASGARD
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Apr 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 22 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top